AI Article Synopsis
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19 and is primarily diagnosed using real-time RT-PCR, which has some accuracy limitations.
- Researchers developed a new peptide-based luminescent immunoassay that detects IgG and IgM antibodies to improve detection.
- The immunoassay showed positive rates of 71.4% for IgG and 57.2% for IgM in confirmed patients, suggesting it could enhance COVID-19 diagnosis when used alongside RT-PCR.
Article Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel β-coronavirus, causes severe pneumonia and has spread throughout the globe rapidly. The disease associated with SARS-CoV-2 infection is named coronavirus disease 2019 (COVID-19). To date, real-time reverse-transcription polymerase chain reaction (RT-PCR) is the only test able to confirm this infection. However, the accuracy of RT-PCR depends on several factors; variations in these factors might significantly lower the sensitivity of detection.
Methods: In this study, we developed a peptide-based luminescent immunoassay that detected immunoglobulin (Ig)G and IgM. The assay cutoff value was determined by evaluating the sera from healthy and infected patients for pathogens other than SARS-CoV-2.
Results: To evaluate assay performance, we detected IgG and IgM in the sera from confirmed patients. The positive rate of IgG and IgM was 71.4% and 57.2%, respectively.
Conclusions: Therefore, combining our immunoassay with real-time RT-PCR might enhance the diagnostic accuracy of COVID-19.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239108 | PMC |
| http://dx.doi.org/10.1093/infdis/jiaa243 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!